No association between the Catechol-O-Methyltransferase (COMT) val158met polymorphism and cognitive improvement following cognitive remediation therapy (CRT) in schizophrenia

Neuroscience Letters

Volumn 496, Issue 2, 2011, Pages 65-69

  Greenwood, Kathryn ^a,b,c   Hung, Chi Fa ^a,d   Tropeano, Maria ^a   McGuffin, Peter ^a   Wykes, Til ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

^c Early Intervention in Psychosis Service   (United Kingdom)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Cognition; Cognitive remediation therapy; COMT; Genotype; Outcome; Schizophrenia

Indexed keywords

CATECHOL METHYLTRANSFERASE; DNA; DOPAMINE; METHIONINE; VALINE;

ADULT; ALLELE; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; COGNITIVE REMEDIATION THERAPY; COGNITIVE THERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN FUNCTION; SCHIZOPHRENIA; TREATMENT RESPONSE; WECHSLER INTELLIGENCE SCALE; WISCONSIN CARD SORTING TEST;

ADULT; CATECHOL O-METHYLTRANSFERASE; COGNITION; COGNITIVE THERAPY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HUMANS; MALE; PREVALENCE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 79955728798     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.03.075     Document Type: Article

References (38)

1. Bertolino A., Caforio G., Blasi G., De Candia M., Latorre V., Petruzzella V., Altamura M., Nappi G., Papa S., Callicott J., Mattay V., Bellomo A., Scarabino T., Weinberger D., Nardini M. Interaction of COMT Val108/158 Met genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry 2004, 161:1798-1805.
2. Bosia M., Bechi M., Marino E., Anselmetti S., Poletti S., Cocchi F., Smeraldi E., Cavallaro R. Influence of catechol-O-methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia. Neurosci. Lett. 2007, 417:271-274.
3. Fioravanti M., Carlone O., Vitale B., Cinti M., Clare L. A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychol. Rev. 2005, 15:73-95.
4. Glatt S., Faraone S., Tsuang M., Glatt S., Faraone S., Tsuang M. Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. Am. J. Psychiatry 2003, 160:469-476.
5. Goldberg T., Goldman R., Burdick K., Malhotra A., Lencz T., Patel R., Woerner M., Schooler N., Kane J., Robinson D. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch. Gen. Psychiatry 2007, 64:1115-1122.
6. Goldman-Rakic P., Muly I., Williams G. D1 receptors in prefrontal cells and circuits. Brain Res. Rev. 2000, 31:295-301.
7. Grace A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991, 41:1-24.
8. Green M., Kern R., Braff D., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff" ?. Schizophr. Bull. 2000, 26:119-136.
9. Guy W. Clinical Global Impression ECDEU Assessment Manual for Psychopharmacology, Revised 1976, National Institute of Mental Health, Rockville, MD.
10. Harrison P., Tunbridge E. Catechol-O-methyltransferase (COMT): a gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders. Neuropsychopharmacology 2007, 33:3037-3045.
11. Husted J, Lim S., Chow E., Greenwood C., Bassett A. Heritability of neurocognitive traits in familial schizophrenia. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2009, 150B:845-853.
12. Insel T.R. Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Arch. Gen. Psychiatry 2009, 66:128-133.
13. Karoum F., Chrapusta S., Egan M. 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J. Neurochem. 1994, 63:972-979.
14. Kay S, Fiszbein A., Opler L. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-275.
15. Kraus M., Keefe R. Cognition as an outcome measure in schizophrenia. Br. J. Psychiatry 2007, 191:s46-51.
16. Kravariti E., Morgan K., Fearon P., Zanelli J., Lappin J., Dazzan P., Morgan C., Doody G., Harrison G., Jones P., Murray R., Reichenberg A. Neuropsychological functioning in first episode schizophrenia. Br. J. Psychiatry 2009, 195:336-345.
17. Kremen W., Eisen S., Tsuang M., Lyons M. Is the Wisconsin Card Sorting Test a useful neurocognitive endophenotype?. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2007, 144B:403-406.
18. Leucht S., Kane J., Kissling W., Hamann J., Etschel E., Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. Br. J. Psychiatry 2005, 187:366-371.
19. Leucht S., Kane J., Kissling W., Hamann J., Etschel E., Engel R. What does the PANSS mean?. Schizophr. Res. 2005, 79:231-238.
20. Lotta T., Vidgren J., Tilgmann C., Ulmanen I., Melen K., Julkunen I., Taskinen J. Kinetics of human soluble and membrane-bound catechol o-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995, 34:4202-4210.
21. Nolan K., Bilder R., Lachman H., Volavka J. Catechol O-methyltransferase Val158Met polymorphism in schizophrenia: differential effects of Val and Met alleles on cognitive stability and flexibility. Am. J. Psychiatry 2004, 161:359-361.
22. Okochi T., Ikeda M., Kishi T., Kawashima K., Kinoshita Y., Kitajima T., Yamanouchi Y., Tomita M., Inada T., Ozaki N., Iwata N. Meta-analysis of association between genetic variants in COMT and schizophrenia: an update. Schizophr. Res. 2009, 110:140-148.
23. Opgen-Rhein C., Neuhaus A., Urbanek C., Hahn E., Sander T., Dettling M. Executive attention in schizophrenic males and the impact of COMT Val108/158Met genotype on performance on the attention network test. Schizophr. Bull. 2008, 34:1231-1239.
24. Overall J., Gorham D. The Brief Psychiatric Rating Scale. Psychol. Rep. 1962, 10:799-812.
25. Palmer B., Dawes S., Heaton R. What do we know about neuropsychological aspects of schizophrenia?. Neuropsychol. Rev. 2009, 19:365-384.
26. Penades R., Catalan R., Salamero M., Boget T., Puig O., Guarch J., Gasto C. Cognitive remediation therapy for outpatients with chronic schizophrenia: a controlled and randomized study. Schizophr. Res. 2006, 87:323-331.
27. Snitz B., MacDonald A., Carter C. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr. Bull. 2006, 32:179-194.
28. SPSS for Windows 2008, SPSS Inc., Chicago.
29. Weickert T., Goldberg T., Mishara A., Apud J., Kolachana B., Egan M., Weinberger D. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol. Psychiatry 2004, 56:677-682.
30. Weinshilboum R., Otterness D., Szumlanski C. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu. Rev. Pharmacol. Toxicol. 1999, 39:19-52.
31. Winterer G, Egan M., Kolachana B., Goldberg T., Coppola R., Weinberger D. Prefrontal electrophysiologic "noise" and catechol-O-methyltransferase genotype in schizophrenia. Biol. Psychiatry 2006, 60:578-584.
32. Woodward N., Jayathilake K., Meltzer H.Y. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr. Res. 2007, 90:86-96.
33. Wykes T, Brammer M., Mellers J., Bray P., Reeder C., Williams C., Corner J. Effects on the brain of a psychological treatment: cognitive remediation therapy: functional magnetic resonance imaging in schizophrenia. Br. J. Psychiatry 2002, 181:144-152.
34. Wykes T., Huddy V. Cognitive remediation for schizophrenia: it is even more complicated. Curr. Opin. Psychiatry 2009, 22:161-167.
35. T. Wykes, V. Huddy, C. Cellard, S. McGurk, P. Czobar, A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry, first published on Mar 15, 2011, doi:10.1176/appi.ajp.2010.10060855.
36. Wykes T., Newton E., Landau S., Rice C., Thompson N., Frangou S. Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: an exploratory randomized controlled trial. Schizophr. Res. 2007, 94:221-230.
37. Wykes T., Reeder C., Landau S., Everitt B., Knapp M., Patel A., Romeo R. Cognitive remediation therapy in schizophrenia: randomised controlled trial. Br. J. Psychiatry 2007, 190:421-427.
38. Wykes T., Reeder C., Williams C., Corner J., Rice C., Everitt B. Are the effects of cognitive remediation therapy (CRT) durable? Results from an exploratory trial in schizophrenia. Schizophr. Res. 2003, 61:163-174.